official US government regulator; press release and programme page detailing eligible drugs, patient criteria, and the July 1-December 2027 demonstration window
관점별 · 1 시각 이번 호 전체
CMS (Centers for Medicare & Medicaid Services) · United States · Medicare begins covering GLP-1 obesity drugs for first time, capping patient cost at $50 a month
CMS confirmed that Zepbound (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk) are the initially approved drugs under the Bridge, with the KwikPen formulation of Zepbound specifically listed. The agency said the program is a time-limited CMS Innovation Center demonstration and that participation requires beneficiaries to enroll through their existing Part D plan.
“CMS to provide $50 monthly access to GLP-1 medications for Medicare beneficiaries.”